Canadian Consensus Recommendations for the Management of Operable Stage II/III Non-Small-Cell Lung Cancer: Results of a Modified Delphi Process

Overview

Journal Curr Oncol

Publisher MDPI

Specialty Oncology

Date 2023 Dec 22

PMID 38132389

Authors

James Tankel

Jonathan Spicer

Quincy Chu

Pierre Olivier Fiset

Biniam Kidane

Natasha B Leighl

Philippe Joubert

Donna Maziak

David Palma

Anna McGuire

Barbara Melosky

Stephanie Snow

Houda Bahig

Normand Blais

Affiliations

Soon will be listed here.

Abstract

The treatment paradigm for patients with stage II/III non-small-cell lung cancer (NSCLC) is rapidly evolving. We performed a modified Delphi process culminating at the Early-stage Lung cancer International eXpert Retreat (ELIXR23) meeting held in Montreal, Canada, in June 2023. Participants included medical and radiation oncologists, thoracic surgeons and pathologists from across Quebec. Statements relating to diagnosis and treatment paradigms in the preoperative, operative and postoperative time periods were generated and modified until all held a high level of consensus. These statements are aimed to help guide clinicians involved in the treatment of patients with stage II/III NSCLC.

Citing Articles

Lobectomy versus segmentectomy in patients with T1N2 non-small cell lung cancer: An analysis of the National Cancer Database.

Iwai Y, Tasoudis P, Agala C, Khoury A, OHara Garcia D, Long J JTCVS Open. 2024; 21:304-312.

PMID: 39534328 PMC: 11551307. DOI: 10.1016/j.xjon.2024.08.003.

Revamping Non-Small Cell Lung Cancer Treatments in Stages II and III: Preparing Healthcare for Cutting-Edge Immuno-Oncology Regimens.

Bertolaccini L, Casiraghi M, Bardoni C, Diotti C, Chiari M, Mazzella A Cancers (Basel). 2024; 16(16).

PMID: 39199613 PMC: 11352981. DOI: 10.3390/cancers16162842.

Barriers and Unequal Access to Timely Molecular Testing Results: Addressing the Inequities in Cancer Care Delays across Canada.

Snow S, Brezden-Masley C, Carter M, Dhani N, Macaulay C, Ramjeesingh R Curr Oncol. 2024; 31(3):1359-1375.

PMID: 38534936 PMC: 10969404. DOI: 10.3390/curroncol31030103.

References

Singh Achrol A, Rennert R, Anders C, Soffietti R, Ahluwalia M, Nayak L . Brain metastases. Nat Rev Dis Primers. 2019; 5(1):5. DOI: 10.1038/s41572-018-0055-y. View

Reck M, Rabe K . Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2017; 377(9):849-861. DOI: 10.1056/NEJMra1703413. View

Rajaram R, Correa A, Xu T, Nguyen Q, Antonoff M, Rice D . Locoregional Control, Overall Survival, and Disease-Free Survival in Stage IIIA (N2) Non-Small-Cell Lung Cancer: Analysis of Resected and Unresected Patients. Clin Lung Cancer. 2020; 21(4):e294-e301. DOI: 10.1016/j.cllc.2020.01.009. View

Chen V, Ruiz B, Hsieh M, Wu X, Ries L, Lewis D . Analysis of stage and clinical/prognostic factors for lung cancer from SEER registries: AJCC staging and collaborative stage data collection system. Cancer. 2014; 120 Suppl 23:3781-92. PMC: 4239667. DOI: 10.1002/cncr.29045. View

Brenner D, Poirier A, Woods R, Ellison L, Billette J, Demers A . Projected estimates of cancer in Canada in 2022. CMAJ. 2022; 194(17):E601-E607. PMC: 9067380. DOI: 10.1503/cmaj.212097. View

Scagliotti G, Pastorino U, Vansteenkiste J, Spaggiari L, Facciolo F, Orlowski T . Randomized phase III study of surgery alone or surgery plus preoperative cisplatin and gemcitabine in stages IB to IIIA non-small-cell lung cancer. J Clin Oncol. 2011; 30(2):172-8. DOI: 10.1200/JCO.2010.33.7089. View

Cagney D, Martin A, Catalano P, Redig A, Lin N, Lee E . Incidence and prognosis of patients with brain metastases at diagnosis of systemic malignancy: a population-based study. Neuro Oncol. 2017; 19(11):1511-1521. PMC: 5737512. DOI: 10.1093/neuonc/nox077. View

Winton T, Livingston R, Johnson D, Rigas J, Johnston M, Butts C . Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005; 352(25):2589-97. DOI: 10.1056/NEJMoa043623. View

Aberle D, Adams A, Berg C, Black W, Clapp J, Fagerstrom R . Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011; 365(5):395-409. PMC: 4356534. DOI: 10.1056/NEJMoa1102873. View

10.

Sorin M, Camilleri-Broet S, Pichette E, Lorange J, Haghandish N, Dube L . Next-generation sequencing of non-small cell lung cancer at a Quebec health care cancer centre. Cancer Treat Res Commun. 2023; 35:100696. DOI: 10.1016/j.ctarc.2023.100696. View

11.

Tsai C, Kung P, Kuo W, Tsai W . Effect of time interval from diagnosis to treatment for non-small cell lung cancer on survival: a national cohort study in Taiwan. BMJ Open. 2020; 10(4):e034351. PMC: 7204926. DOI: 10.1136/bmjopen-2019-034351. View

12.

Herbst R, Wu Y, John T, Grohe C, Majem M, Wang J . Adjuvant Osimertinib for Resected EGFR-Mutated Stage IB-IIIA Non-Small-Cell Lung Cancer: Updated Results From the Phase III Randomized ADAURA Trial. J Clin Oncol. 2023; 41(10):1830-1840. PMC: 10082285. DOI: 10.1200/JCO.22.02186. View

13.

Seitlinger J, Spicer J . Turning the tides on the perioperative care of resectable lung cancer. J Thorac Cardiovasc Surg. 2023; 166(5):1340-1346. DOI: 10.1016/j.jtcvs.2023.01.034. View

14.

Mazieres J, Drilon A, Lusque A, Mhanna L, Cortot A, Mezquita L . Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry. Ann Oncol. 2019; 30(8):1321-1328. PMC: 7389252. DOI: 10.1093/annonc/mdz167. View

15.

Turkmen C, Sonmezoglu K, Toker A, Yilmazbayhan D, Dilege S, Halac M . The additional value of FDG PET imaging for distinguishing N0 or N1 from N2 stage in preoperative staging of non-small cell lung cancer in region where the prevalence of inflammatory lung disease is high. Clin Nucl Med. 2007; 32(8):607-12. DOI: 10.1097/RLU.0b013e3180a1ac87. View

16.

Bakaeen F, Svensson L, Mitchell J, Keshavjee S, Patterson G, Weisel R . The American Association for Thoracic Surgery/Society of Thoracic Surgeons Position Statement on Developing Clinical Practice Documents. Ann Thorac Surg. 2017; 103(4):1350-1356. DOI: 10.1016/j.athoracsur.2017.01.020. View

17.

Rusch V, Giroux D, Kraut M, Crowley J, Hazuka M, Winton T . Induction chemoradiation and surgical resection for superior sulcus non-small-cell lung carcinomas: long-term results of Southwest Oncology Group Trial 9416 (Intergroup Trial 0160). J Clin Oncol. 2007; 25(3):313-8. DOI: 10.1200/JCO.2006.08.2826. View

18.

Bridges J, Mohamed A, Finnern H, Woehl A, Hauber A . Patients' preferences for treatment outcomes for advanced non-small cell lung cancer: a conjoint analysis. Lung Cancer. 2012; 77(1):224-31. DOI: 10.1016/j.lungcan.2012.01.016. View

19.

Lv C, Fang W, Wu N, Jiao W, Xu S, Ma H . Osimertinib as neoadjuvant therapy in patients with EGFR-mutant resectable stage II-IIIB lung adenocarcinoma (NEOS): A multicenter, single-arm, open-label phase 2b trial. Lung Cancer. 2023; 178:151-156. DOI: 10.1016/j.lungcan.2023.02.011. View

20.

Halperin J, Levine G, Al-Khatib S, Birtcher K, Bozkurt B, Brindis R . Further Evolution of the ACC/AHA Clinical Practice Guideline Recommendation Classification System: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Circulation. 2015; 133(14):1426-8. DOI: 10.1161/CIR.0000000000000312. View